Experimental drug is first targeted therapy to improve survival in high-risk AML patients
Monday, December 7, 2015 - 13:30
in Health & Medicine
Midostaurin added to standard chemotherapy is the first targeted treatment to improve survival of a high-risk, genetically defined subgroup of patients with acute myeloid leukemia according to new research.